Shanghai Kaibao Pharmaceutical Co (SZSE:300039) GF Value : ¥8.94 (As of Jun. 17, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-06-17), Shanghai Kaibao Pharmaceutical Co's share price is ¥5.68. Shanghai Kaibao Pharmaceutical Co's GF Value is ¥8.94. Therefore, Shanghai Kaibao Pharmaceutical Co's Price-to-GF-Value for today is 0.64.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Shanghai Kaibao Pharmaceutical Co is Significantly Undervalued.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Shanghai Kaibao Pharmaceutical Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	5.68	/	8.94
	=	0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Kaibao Pharmaceutical Co GF Value Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » GF Value

Traded in Other Exchanges

N/A

Address

88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401

Website

http://www.xykb.com

Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.

Executives

Liu Shao Yong	Supervisors
Ren Li Wang	Secretary Dong
Zhang Tao	Executives
Mu Jing Wei	Director
Li Xiu Hai	Directors, executives
Zhang Lian Xin	Supervisors
Han Jing	Independent director
Wang Guo Ming	Directors, executives
Wang Chong Bang	Executives
Liu Yi Shan	Director
Li Qing Wei	Independent director
Mu Lai An	Director
Zhu Ying Jun	Executives
Chang Qing Ling	Supervisors
Zhang Peng	Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines